Mary Bucci, MD
Radiation Oncology · Albuquerque, NMNPI 1285727883
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $933 of the $1,398 with a category attached, or 66.7%. 18 manufacturers reported payments, led by Varian Medical Systems, Inc. at 28.7% of the total. Reporting peaked in 2019 at $584 and has fallen 78.0% since, to $128 in 2025.
Across 27 payments — averaging $51.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Varian Medical Systems, Inc.$401
- AstraZeneca$227
- Visionrt, Inc.$125
- Blue Earth Diagnostics$123
- Eisai Inc.$119
- Johnson & Johnson$111
- plus $292 from 12 others
What the payments were for
- Travel & lodging$30722%
- Food & beverage$93367%
- Education$15811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Varian Medical Systems, Inc. | 3 | $401 |
| AstraZeneca | 4 | $227 |
| Visionrt, Inc. | 1 | $125 |
| Blue Earth Diagnostics | 1 | $123 |
| Eisai Inc. | 1 | $119 |
| Johnson & Johnson | 2 | $111 |
| Boston Scientific | 3 | $46 |
| Gilead | 2 | $40 |
| Bioprotect Medical, Inc. | 1 | $33 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| AbbVie | 1 | $22 |
| EMD Serono, Inc. | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Qfix | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,398 in reported general payments places this provider in the 85th percentile of 24 radiation oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 73 | $1,735 |
| Dexamethasone | 16 | $131 |
| Tamsulosin Hcl | 11 | $109 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Albuquerque
- Gregg FranklinAlbuquerque$75K
- Patrick BeagenAlbuquerque$1K
- Thomas SchroederAlbuquerque$811
- Jeremiah JohnsonAlbuquerque$770
- David LeeAlbuquerque$674
- Utkarsh ShuklaAlbuquerque$531
- Paul AnthonyAlbuquerque$378
- Ramesh GopalAlbuquerque$367
- Benny LiemAlbuquerque$163
- Amanda StoryAlbuquerque$138
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.